Lipton A - Search Results

1

Innovations and challenges in renal cancer: consensus statement from the first international conference.

Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG Jr, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Atkins MB, et al. Among authors: lipton a. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6277S-81S. doi: 10.1158/1078-0432.CCR-040720. Clin Cancer Res. 2004. PMID: 15448017 Review. No abstract available.

2

Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Lipton A, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6397S-403S. doi: 10.1158/1078-0432.CCR-040030. Clin Cancer Res. 2004. PMID: 15448038 Review.

3

Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.

Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L. Lipton A, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6209s-6212s. doi: 10.1158/1078-0432.CCR-06-1213. Clin Cancer Res. 2006. PMID: 17062702 Free PMC article.

4

Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.

Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Coleman RE, et al. Among authors: lipton a. Clin Cancer Res. 2008 Oct 15;14(20):6387-95. doi: 10.1158/1078-0432.CCR-08-1572. Clin Cancer Res. 2008. PMID: 18927277 Free PMC article. Review.

5

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.

Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJ. Lipton A, et al. Clin Cancer Res. 2016 Dec 1;22(23):5713-5721. doi: 10.1158/1078-0432.CCR-15-3086. Epub 2016 May 2. Clin Cancer Res. 2016. PMID: 27140926 Free article. Clinical Trial.

6

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.

Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A. Oh WK, et al. Among authors: lipton a. Cancer. 2011 Feb 1;117(3):517-25. doi: 10.1002/cncr.25394. Epub 2010 Sep 22. Cancer. 2011. PMID: 20862742 Free article.

7

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.

Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard KI, Ingle JN, Budd GT, Ellis MJ, Sledge GW, Rabaglio M, Han L, Elliott CR, Shepherd LE, Goss PE, Ali SM. Lipton A, et al. Cancer. 2017 Jul 1;123(13):2444-2451. doi: 10.1002/cncr.30682. Epub 2017 May 2. Cancer. 2017. PMID: 28464211 Free article. Clinical Trial.

8

Predicting response to herceptin therapy.

Lipton A, Leitzel K, Ali S. Lipton A, et al. Clin Cancer Res. 2004 Mar 1;10(5):1559-60. doi: 10.1158/1078-0432.ccr-1221-3. Clin Cancer Res. 2004. PMID: 15014003 No abstract available.

9

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

Lipton A, Zheng M, Seaman J. Lipton A, et al. Cancer. 2003 Sep 1;98(5):962-9. doi: 10.1002/cncr.11571. Cancer. 2003. PMID: 12942563 Free article. Clinical Trial.

10

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. Lipton A, et al. Cancer Invest. 2002;20 Suppl 2:45-54. doi: 10.1081/cnv-120014886. Cancer Invest. 2002. PMID: 12442349 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

509 results

Search Page